About pliant therapeutics inc - PLRX
Pliant Therapeutics, Inc. engages in the discovery, development and commercialization of therapies for fibrotic diseases. It offers a product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
PLRX At a Glance
Pliant Therapeutics, Inc.
331 Oyster Point Boulevard
South San Francisco, California 94080
| Phone | 1-650-481-6770 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -149,344,000.00 | |
| Sector | Health Technology | Employees | 49 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PLRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.414 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.586 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.335 |
PLRX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -3,047,836.735 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PLRX Liquidity
| Current Ratio | 12.004 |
| Quick Ratio | 12.004 |
| Cash Ratio | 11.668 |
PLRX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -47.599 |
| Return on Equity | -61.549 |
| Return on Total Capital | -71.011 |
| Return on Invested Capital | -52.164 |
PLRX Capital Structure
| Total Debt to Total Equity | 16.062 |
| Total Debt to Total Capital | 13.839 |
| Total Debt to Total Assets | 12.623 |
| Long-Term Debt to Equity | 15.263 |
| Long-Term Debt to Total Capital | 13.151 |